Skip to main content
Log in

Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Objective

To develop a model to predict annual hospital costs for patients with established renal failure, taking into account the effect of patient and treatment characteristics of potential relevance for conducting an economic evaluation, such as age, comorbidities and time on treatment. The analysis focuses on factors leading to variations in inpatient and outpatient costs and excludes fixed costs associated with dialysis, transplant surgery and high cost drugs.

Methods

Annual costs of inpatient and outpatient hospital episodes for patients starting renal replacement therapy in England were obtained from a large retrospective dataset. Multiple imputation was performed to estimate missing costs due to administrative censoring. Two-part models were developed using logistic regression to first predict the probability of incurring any hospital costs before fitting generalised linear models to estimate the level of cost in patients with positive costs. Separate models were developed to predict inpatient and outpatient costs for each treatment modality.

Results

Data on hospital costs were available for 15,869 incident dialysis patients and 4511 incident transplant patients. The two-part models showed a decreasing trend in costs with increasing number of years on treatment, with the exception of dialysis outpatient costs. Age did not have a consistent effect on hospital costs; however, comorbidities such as diabetes and peripheral vascular disease were strong predictors of higher hospital costs in all four models.

Conclusion

Analysis of patient-level data can result in a deeper understanding of factors associated with variations in hospital costs and can improve the accuracy with which costs are estimated in the context of economic evaluations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Tonelli, M., Wiebe, N., Knoll, G., Bello, A., Browne, S., Jadhav, D., Klarenbach, S., Gill, J.: Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am. J. Transplant. 11(10), 2093–2109 (2011)

    Article  CAS  PubMed  Google Scholar 

  2. Department of Health. The National Service Framework for renal services. Part one: dialysis and transplantation (2004), https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/199001/National_Service_Framework_for_Renal_Services_Part_One_-_Dialysis_and_Transplantation.pdf. Accessed 16 July 2014

  3. Rao, A., Steenkamp, R., Caskey, F.: UK Renal Registry 16th annual report. Chapter 5. Comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales and Northern Ireland from 2011 to 2012. Nephron. Clin. Pract 125, 99–110 (2013)

    Article  PubMed  Google Scholar 

  4. Metcalfe, W., Khan, I.H., Prescott, G.J., Simpson, K., Macleod, A.M.: Hospitalization in the first year of renal replacement therapy for end-stage renal disease. QJM 96(12), 899–909 (2003)

    Article  CAS  PubMed  Google Scholar 

  5. Hospital episode statistics, http://www.hscic.gov.uk/hes. Accessed 2 April 2015

  6. Fotheringham, J., Fogarty, D., Jacques, R., ElNahas, M., Campbell, M.: Chapter 13. The linkage of incident renal replacement therapy patients in England (2002–2006) to hospital episodes and national mortality data: improved demography and hospitalisation data in patients undergoing renal replacement therapy. Nephron. Clin. Pract 120(Suppl 1), c247–c260 (2012)

    Article  PubMed  Google Scholar 

  7. UK Renal Registry, https://www.renalreg.org/datasets/the-uk-renal-registry-dataset/. Accessed 2 April 2015

  8. Department of Health. Confirmation of payment by results (PbR) arrangements for 2011-12, 2011-12 tariff information spreadsheet. http://webarchive.nationalarchives.gov.uk/20130507170152/https:/www.gov.uk/government/publications/confirmation-of-payment-by-results-pbr-arrangements-for-2011-12. Accessed 21 January 2014

  9. Mullahy, J.: Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J. Health. Econ. 17(3), 247–281 (1998)

    Article  CAS  PubMed  Google Scholar 

  10. Dunn, G., Mirandola, M., Amaddeo, F., Tansella, M.: Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review. Br. J. Psychiatry 183, 398–404 (2003)

    Article  PubMed  Google Scholar 

  11. Buntin, M.B., Zaslavsky, A.M.: Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J. Health. Econ. 23(3), 525–542 (2004)

    Article  PubMed  Google Scholar 

  12. Barber, J., Thompson, S.: Multiple regression of cost data: use of generalised linear models. J. Health Serv. Res. Policy 9(4), 197–204 (2004)

    Article  PubMed  Google Scholar 

  13. Hardin, J.W.H., J.M.: Generalized linear models and extensions, 2nd ed. Stata Press, Lakeway Drive, Texas (2007)

  14. Kirkwood, B.R., Sterne, J.A.C.: Essential medical statistics, 2nd ed. Blackwell Publishing Oxford (2003)

  15. Haller, M., Gutjahr, G., Kramar, R., Harnoncourt, F., Oberbauer, R.: Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol. Dial. Transplant. 26(9), 2988–2995 (2011)

    Article  PubMed  Google Scholar 

  16. Howard, K., Salkeld, G., White, S., McDonald, S., Chadban, S., Craig, J.C., Cass, A.: The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology 14(1), 123–132 (2009)

    Article  PubMed  Google Scholar 

  17. Jassal, S.V., Krahn, M.D., Naglie, G., Zaltzman, J.S., Roscoe, J.M., Cole, E.H., Redelmeier, D.A.: Kidney transplantation in the elderly: a decision analysis. J. Am. Soc. Nephrol. 14(1), 187–196 (2003)

    Article  PubMed  Google Scholar 

  18. Kontodimopoulos, N., Niakas, D.: An estimate of lifelong costs and QALYs in renal replacement therapy based on patientsʼ life expectancy. Health Policy 86, 85–96 (2008)

    Article  PubMed  Google Scholar 

  19. de Wit, G.A., Ramsteijn, P.G., de Charro, F.T.: Economic evaluation of end stage renal disease treatment. Health Policy 44, 215–232 (1998)

    Article  PubMed  Google Scholar 

  20. Wong, G., Howard, K., Chapman, J.R., Chadban, S., Cross, N., Tong, A., Webster, A.C., Craig, J.C.: Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PLoS one 7(1) (2012)

  21. Briggs, A., Clark, T., Wolstenholme, J., Clarke, P.: Missing… presumed at random: cost-analysis of incomplete data. Health Econ. 12(5), 377–392 (2003)

    Article  PubMed  Google Scholar 

  22. Sterne, J.A., White, I.R., Carlin, J.B., Spratt, M., Royston, P., Kenward, M.G., Wood, A.M., Carpenter, J.R.: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338, b2393 (2009)

    Article  PubMed  PubMed Central  Google Scholar 

  23. Bang, H.T., Tsiatis, A.A.: Estimating medical costs with censored data. Biometrika 87, 329–343 (2000)

    Article  Google Scholar 

  24. Carides, G.W., Heyse, J.F., Iglewicz, B.: A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics 1(3), 299–313 (2000)

    Article  CAS  PubMed  Google Scholar 

  25. Lin, D.Y., Feuer, E.J., Etzioni, R., Wax, Y.: Estimating medical costs from incomplete follow-up data. Biometrics 53(2), 419–434 (1997)

    Article  CAS  PubMed  Google Scholar 

  26. O’Hagan, A., Stevens, J.W.: On estimators of medical costs with censored data. J. Health Econ. 23(3), 615–625 (2004)

    Article  PubMed  Google Scholar 

  27. Young, T.A.: Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 23(12), 1229–1242 (2005)

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This article presents independent research commissioned by the National Institute for Health Research (NIHR) under the Programme Grant for Applied Research (RP-PG-0109-10116) entitled Access to Transplantation and Transplant Outcome Measures (ATTOM). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. JF was funded by a Kidney Research UK Clinical Training Fellowship. The ATTOM Study Group comprises: J. Andrew Bradley, Clare Bradley, John Cairns, Heather Draper, Chris Dudley, John L. Forsythe, Damian G. Fogarty, Rachel J. Johnson, Geraldine Leydon, Wendy Metcalfe, Gabriel C. Oniscu, Rommel Ravanan, Paul Roderick, Charles R. Tomson and Christopher Watson. The authors are grateful to the UK Renal Registry and Hospital Episode Statistics for the linked dataset. Hospital Episode Statistics: Copyright 2014, re-used with the permission of the Health and Social Care Information Centre. All rights reserved.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Bernadette Li.

Additional information

A full list of members of the Access to Transplantation and Transplant Outcome Measures (ATTOM) Study Group is provided in the Acknowledgments.

Appendix: A worked example to predict hospital costs based on the final two-part model

Appendix: A worked example to predict hospital costs based on the final two-part model

To estimate annual inpatient costs for a 55-year-old male patient with diabetes who has been on haemodialysis for 3 years:

Part 1: probability of incurring any inpatient cost >£0

Taking the natural log of the odds ratios in Table 3, calculate log odds of incurring any inpatient cost

$$\begin{aligned} {\text{CONSTANT }} + \left( {\beta 1 \times {\text{AGEGROUP}}50 - 64} \right) + \left( {\beta 2 \times {\text{YEAR}}3} \right) + \left( {\beta 3 \times {\text{DIABETES}}} \right) \hfill \\ = 0.850 + \left( { - 0.022 \times 1} \right) + \left( { - 0.702 \times 1} \right) + \left( {0.242 \times 1} \right) = 0.368 \hfill \\ \end{aligned}$$

Calculate probability from log odds

$$e^{x\beta } / \left( {1 + e^{x\beta } } \right) = e^{0.368} / \left( {1 + e^{0.368} } \right) = 0.591$$

Part 2: estimate level of inpatient cost based on coefficients in Table 5

$$\begin{aligned} {\text{CONSTANT}} + \left( {\beta 1 \times {\text{AGEGROUP}}50 - 64} \right) + \left( {\beta 2 \times {\text{YEAR}}3} \right) + \left( {\beta 3 \times {\text{DIABETES}}} \right) \hfill \\ = 7782 + \left( { - 170 \times 1} \right) + \left( { - 1434 \times 1} \right) + \left( {1191 \times 1} \right) = \pounds 7368 \hfill \\ \end{aligned}$$

Combine parts 1 and 2: multiply estimated level of inpatient cost by probability of incurring any cost

$$\pounds 7368 \times 0.591 = \pounds 4354$$

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, B., Cairns, J., Fotheringham, J. et al. Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation. Eur J Health Econ 17, 659–668 (2016). https://doi.org/10.1007/s10198-015-0705-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-015-0705-x

Keywords

JEL-Classification:

Navigation